By lowering BRCA1’s ability to repair DNA, the high expression of RING domain-deficient BRCA1 proteins in breast cancer cell lines increases resistance to cisplatin and PARPi, while deletion mutations in BRCA2 would result in resistance to PARPi (11). This evidence concerns the gene BRCA2 and breast cancer.